当前位置:首页 - 行情中心 - 维力医疗(603309) - 财务分析 - 利润表

维力医疗

(603309)

  

流通市值:37.71亿  总市值:37.84亿
流通股本:2.92亿   总股本:2.93亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入348,152,134.381,509,335,256.031,060,429,057.46676,250,749.96
营业收入348,152,134.381,509,335,256.031,060,429,057.46676,250,749.96
二、营业总成本279,072,044.81,254,900,116.55874,790,564.58551,484,535.72
营业成本192,256,355.32837,189,388.83585,377,707.53371,467,679.15
税金及附加4,320,619.6416,313,055.0711,244,847.937,858,838.27
销售费用28,727,694.8158,218,403.91108,203,581.9266,406,839.51
管理费用30,232,203.45129,920,814.4597,387,037.6262,135,865.56
研发费用21,233,816.26111,112,162.6866,811,813.943,125,049.46
财务费用2,301,355.332,146,291.615,765,575.68490,263.77
其中:利息费用2,346,564.412,315,532.147,688,612.545,013,258.09
其中:利息收入1,142,746.165,631,835.854,820,310.963,289,826.17
加:公允价值变动收益628,851.62619,061.73171,547.83863,236.91
加:投资收益676,864.986,691,645.985,411,823.742,963,477.1
资产处置收益-2,304.82428,433.9167,434.7912,275.4
资产减值损失(新)-1,591,797.14-9,269,486.144,539.54-1,612,063.91
信用减值损失(新)-57,850.18-18,466.35-28,490.69-442,884.11
其他收益3,034,871.812,612,806.099,442,844.445,798,547.92
营业利润平衡项目0000
四、营业利润71,768,725.84265,499,134.74200,748,192.53132,348,803.55
加:营业外收入58,221.63347,683.57526,276.07230,270.42
减:营业外支出124,480.182,803,286.492,094,074.821,311,305.76
利润总额平衡项目0000
五、利润总额71,702,467.29263,043,531.82199,180,393.78131,267,768.21
减:所得税费用11,121,679.7834,572,491.1526,983,389.8420,662,595.22
六、净利润60,580,787.5228,471,040.67172,197,003.94110,605,172.99
持续经营净利润60,580,787.5228,471,040.67172,197,003.94110,605,172.99
归属于母公司股东的净利润58,923,751.17219,393,029.14166,726,371.77106,053,566.29
少数股东损益1,657,036.339,078,011.535,470,632.174,551,606.7
(一)基本每股收益0.20.750.570.36
(二)稀释每股收益0.20.750.570.36
八、其他综合收益364,312.09-944,789.73--
归属于母公司股东的其他综合收益346,096.49-897,550.24--
九、综合收益总额60,945,099.59227,526,250.94172,197,003.94110,605,172.99
归属于母公司股东的综合收益总额59,269,847.66218,495,478.9166,726,371.77106,053,566.29
归属于少数股东的综合收益总额1,675,251.939,030,772.045,470,632.174,551,606.7
公告日期2025-04-252025-04-252024-10-192024-07-26
审计意见(境内)标准无保留意见
TOP↑